Anuh Pharma reclassifies nine shareholders to public category

1 min read     Updated on 26 May 2026, 04:35 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Anuh Pharma Limited applied to exchanges on May 25, 2026 to reclassify nine shareholders from the promoter group to the public category under Regulation 31A of SEBI LODR Regulations, 2015. The shareholders, holding 0.95% of the paid-up capital, are immediate relatives of promoters no longer involved in management.

powered bylight_fuzz_icon
40739568

*this image is generated using AI for illustrative purposes only.

Anuh Pharma Limited has applied to the stock exchanges on May 25, 2026 to reclassify nine shareholders from the promoter group to the public category. The application follows a Board meeting held on May 20, 2026, which approved the requests received from these shareholders on May 19, 2026. The reclassification is sought under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The shareholders collectively hold 9,49,988 equity shares, representing 0.95% of the company's total paid-up share capital. The applicants include Kinjal Siddharth Jhaveri, who holds the largest portion among the applicants at 0.81%, and others such as Nina Vijay Shah and Hemant Babubhai Choksi.

Details of Shareholders Seeking Reclassification

The following table outlines the shareholders approved for reclassification along with their respective holdings:

Sr No. Name Number of Equity shares held % of shareholding
1. Madhurika Narendra Shah 12,000 0.01
2. Hemant Babubhai Choksi 24,000 0.02
3. Mukesh Kantilal Shah 14,400 0.01
4. Aruna Navnit Shah 5,040 0.01
5. Vikram Kirtilal Shah 200 0.00
6. Kiran Piyush Shah 15,388 0.02
7. Kinjal Siddharth Jhaveri 8,16,160 0.81
8. Nina Vijay Shah 60,000 0.06
9. Neela Pradeep Shah 2,800 0.003
TOTAL 9,49,988 0.95

Regulatory Compliance and Undertakings

The Board confirmed that these individuals are immediate relatives of promoters and are no longer involved in the day-to-day affairs or management of anuh pharma . They stated that they do not exercise control over the company's affairs or possess special rights through formal or informal arrangements.

The outgoing promoters confirmed they do not hold more than 10% of the total voting rights, are not represented on the Board of Directors, and do not act as key managerial personnel. They also verified that they are not wilful defaulters or fugitive economic offenders, and there is no pending regulatory action against them.

Historical Stock Returns for Anuh Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+3.87%+7.07%+2.90%+3.56%-24.33%-27.43%

How will the increase in public shareholding to 0.95% impact Anuh Pharma's ability to meet minimum public float requirements?

Does this reclassification signal a broader trend of promoter family members reducing their involvement in the company's management?

Could this shift in shareholding structure lead to changes in the company's corporate governance policies?

Anuh Pharma Gets WHO Prequalification for Anti-Malarial API Amodiaquine Hydrochloride USP

1 min read     Updated on 05 May 2026, 08:35 PM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Anuh Pharma Limited secured WHO Prequalification approval for Amodiaquine Hydrochloride USP, an anti-malarial Active Pharmaceutical Ingredient compliant with United States Pharmacopeia standards. The approval, disclosed on 04 May 2026 under SEBI Regulation 30, covers international markets including WHO-procured and donor-funded programmes, consolidating the company's position as a preferred global API supplier for anti-malarial treatments.

powered bylight_fuzz_icon
39506014

*this image is generated using AI for illustrative purposes only.

Anuh Pharma Limited has received World Health Organization (WHO) Prequalification approval for its Active Pharmaceutical Ingredient (API), Amodiaquine Hydrochloride USP. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and was communicated to stock exchanges on 04 May 2026. This regulatory milestone reinforces the company's standing as a credible supplier for international anti-malarial programmes.

WHO Prequalification: A Key Regulatory Milestone

The WHO Prequalification programme is an internationally recognised certification that enables pharmaceutical manufacturers to demonstrate compliance with rigorous global quality, safety, and efficacy standards. Approval under this programme is particularly significant for APIs intended for use in public health programmes and procurement by international health agencies. The following table summarises the key details of the approved product:

Parameter: Details
Product Name: Amodiaquine Hydrochloride USP (Amodiaquine HCl USP)
Drug Category: Anti-Malarial API (Active Pharmaceutical Ingredient)
Pharmacopoeial Standard: United States Pharmacopeia (USP)
Approval Body: World Health Organization (WHO) – Prequalification Programme
Approval Type: WHO Prequalification of Medicines Programme – Active Pharmaceutical Ingredient
Applicable Market: International markets including WHO-procured and donor-funded programmes

About Amodiaquine Hydrochloride USP

Amodiaquine Hydrochloride is an essential medicine listed by the WHO and is widely used in combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria. As an API, it forms the active core of finished anti-malarial formulations deployed across global health programmes. The WHO Prequalification of this product by Anuh Pharma validates the company's manufacturing capabilities against stringent international benchmarks and positions it as a preferred API supplier for global anti-malarial programmes, including those funded by donor agencies.

Historical Stock Returns for Anuh Pharma

1 Day5 Days1 Month6 Months1 Year5 Years
+3.87%+7.07%+2.90%+3.56%-24.33%-27.43%

Which specific international donor agencies or procurement bodies like UNICEF and Global Fund is Anuh Pharma targeting for supply contracts following this WHO Prequalification approval?

How might this WHO Prequalification approval impact Anuh Pharma's revenue mix between domestic and international markets over the next 2-3 years?

Are there other APIs in Anuh Pharma's pipeline that are currently undergoing or planned for WHO Prequalification, potentially expanding their global health programme footprint?

More News on Anuh Pharma

1 Year Returns:-24.33%